AUA 2017: Late-Breaking Abstract – Interim results from a single-arm multicenter Phase II trial of CG0070, an oncolytic adenovirus, for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC)

Boston, MA ( Despite the recent excitement with the breakthrough immunotherapy for advanced muscle-invasive bladder cancer, no new therapy has shown efficacy for non-muscle invasive disease unresponsive to BCG treatment. Kamat et al recently constructed guidelines on clinical trial design, defining BCG-unresponsive disease, as well as proposing therapeutic goals for conservative therapies in the BCG-unresponsive setting. This study is an extension of the ongoing effort to treat high risk, recurrent NMIBC while preserving the bladder. The investigators used a novel replication selective oncolytic adenovirus CG0070, which destroys bladder tumor cells through their defective retinoblastoma pathway. In this interim analysis of 36 patients, overall 6 month CR rate was 44%. The highest response rates were seen in pure CIS, while those with pure T1 disease or mixed CIS and Ta/T1 papillary disease had the worst outcomes. The therapy is relatively safe, with no grade 4/5 complications reported to date. Final results from this trial are eagerly awaited.

Presenter: Vignesh Packiam

Written By: Roger Li MD Urologic Oncology Fellow, UT MD Anderson Cancer Center @UrogerliMD
Ashish M. Kamat MD Wayne B. Duddlesten Professor, UT MD Anderson Cancer Center

at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.